Medtronic data should lead to approval of drug-coated balloon, says Wells Fargo Wells fargo believes that data from a trial of Medtronic's drug-coated balloon will lead to approval of the device in 1H15 and establish the company as the market leader in the space. After analyzing data, the firm thinks data on a competing device from C.R. Bard (BCR) could be significantly less positive than the data on Medtronic's product. As a result, the firm anticipates that Medtronic will have a marketing advantage over C.R. Bard. Wells keeps an Outperform rating on Medtronic.